Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pro-Symbioflor in Irritable Bowel Syndrome (Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study)
2012-002741-38Phase 4Completed
- Sponsor
- Symbiopharm
- Start
- Jul 2013
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Pro-Symbioflor with Placebo (2 arms). Primary endpoints: IBS symptom response (primary endpoint 1) and IBS symptom response (primary endpoint 2). Started Jul 2013; status: completed.
02
Drugs
Pro-Symbioflor
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2012-002741-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002741-38.